Skip to main content
Premium Trial:

Request an Annual Quote

Nature Clarifies Role in GEML Community; Denies it Endorses Standard

NEW YORK, Dec 22 - While the Nature Publishing Group has joined Rosetta Inpharmatics's Gene Expression Markup Language Community, the journal " is not taking sides or picking any standard over another," a Nature spokesman said Friday.

" Nature hasn't adopted the language for its authors or reviewers," said Richard Nathan, Nature's director of business development.

This clarification of Nature's role in the GEML community came in response to Rosetta's recent public relations campaign, which claimed the journal " officially endorses" the GEML standard.

The announcement prompted the Microarray Gene Expression Database Group to send a letter to the journal stating that the Microarray Markup Language, which the MGED supports, has wider support in academia and industry.

Nathan noted that Nature joined the GEML community as a means to " participate actively in the development of standards and the development of GEML itself." He said that the journal is " in communication" with both the GEML and MAML communities.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.